Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322473 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study, sponsored by MoonLake Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT05322473: Completed Phase 2 study, sponsored by MoonLake Immunotherapeutics.
NCT05322473 is a Phase 2 study that has completed, run by MoonLake Immunotherapeutics. The registered enrollment target is 234 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05322473, a Phase 2 study, has completed, sponsored by MoonLake Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Primary Outcome
Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), where HiSCR75 is defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count.
Interventions
- OTHER Placebo
- DRUG Adalimumab
- DRUG Sonelokimab (M1095)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 2 |
What the finished NCT05322473 record still lists
NCT05322473 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05322473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05322473 about?
NCT05322473 is a clinical study titled "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
What is the current status of trial NCT05322473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2022-04-25. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT05322473?
The interventions under investigation include: Placebo (OTHER), Adalimumab (DRUG), Sonelokimab (M1095) (DRUG).
Who is sponsoring clinical trial NCT05322473?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05322473's enrollment target sits among peer trials
234 255th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI